Kings College Hospital NHS Foundation Trust, London, United Kingdom.
Leicester Diabetes Center, University of Leicester, Leicester, United Kingdom.
Diabetes Technol Ther. 2024 Mar;26(S3):32-37. doi: 10.1089/dia.2023.0433.
The present report celebrates the benchmarking of 100,000 MiniMed™ 780G system users in Europe, Middle East, and Africa (EMEA) and summarizes the major insights into the usability and outcomes of this system. Carelink Personal data (August 2020-August 2023) of users living in EMEA were analyzed. Continuous glucose monitoring-based endpoints were aggregated for (1) the full cohort and (2) a 12-month longitudinal cohort. Subanalyses were done for users on optimal settings (those spending ≥95% of time with glucose target of 100 mg/dL, and ≥95% of time with active insulin time of 2 h), for self-reported age groups (≤15 and ≥56 years) and for various countries/regions. Data from 101,629 users (34 countries) were analyzed. Mean time in range (TIR) was 72.3%, glucose management indicator (GMI) was 7%, time below 70 mg/dL (TBR70) was 2.0% and time below 54 mg/dL (TBR54) was 0.4%. In terms of international targets, 59.6% of users achieved a GMI <7%, 62.5% a TIR >70%, 88.4% a TBR70 < 4%, and 90.0% a TBR54 < 1%. Data improved impressively in optimal setting users (TIR = 78.8%, and users reaching TIR >70% = 86.3%) while safety remained (TBR70 = 2.2% and TBR54 = 0.4%). Data showed consistency across self-reported age groups and geographies. In the longitudinal cohort, TIR reached 75.5% in the first month and remained 73.3% or higher over the 12-month period. Over 100,000 users of the MiniMed™ 780G system have demonstrated consistency in achieving target control of glycemia.
本报告庆祝了欧洲、中东和非洲（EMEA）地区 100,000 名 MiniMed™ 780G 系统用户的基准测试，并总结了该系统可用性和结果的主要见解。分析了生活在 EMEA 的用户的 Carelink 个人数据（2020 年 8 月至 2023 年 8 月）。基于连续血糖监测的终点数据被汇总为（1）整个队列和（2）12 个月的纵向队列。对于使用最佳设置的用户（那些将血糖目标设定在 100mg/dL 的时间占比≥95%，并且处于活性胰岛素时间≥2h 的时间占比≥95%）、自我报告的年龄组（≤15 岁和≥56 岁）以及不同国家/地区进行了亚组分析。共分析了来自 101,629 名用户（34 个国家）的数据。时间在目标范围内（TIR）为 72.3%，血糖管理指标（GMI）为 7%，血糖值低于 70mg/dL（TBR70）的时间为 2.0%，血糖值低于 54mg/dL（TBR54）的时间为 0.4%。就国际目标而言，59.6%的用户达到 GMI<7%，62.5%的用户达到 TIR>70%，88.4%的用户达到 TBR70<4%，90.0%的用户达到 TBR54<1%。在最佳设置用户中，数据显著改善（TIR=78.8%，达到 TIR>70%的用户=86.3%），同时安全性保持不变（TBR70=2.2%，TBR54=0.4%）。数据在自我报告的年龄组和地理位置上具有一致性。在纵向队列中，TIR 在第一个月达到 75.5%，并在 12 个月期间保持在 73.3%或更高。超过 100,000 名 MiniMed™ 780G 系统用户在实现血糖控制目标方面表现出一致性。
